Document is current
Any future updates will be listed below
-
Authors
Sanborn, Rachel E https://orcid.org/0000-0003-0542-6054
Pishvaian, Michael J
Callahan, Margaret K
Weise, Amy
Sikic, Branimir I
Rahma, Osama
Cho, Daniel C
Rizvi, Naiyer A
Sznol, Mario
Lutzky, Jose https://orcid.org/0000-0002-9503-2130
Bauman, Julie E
Bitting, Rhonda L
Starodub, Alexander
Jimeno, Antonio
Reardon, David A
Kaley, Thomas
Iwamoto, Fabio
Baehring, Joachim M
Subramaniam, Deepa S
Aragon-Ching, Jeanny B
Hawthorne, Thomas R
Rawls, Tracey
Yellin, Michael https://orcid.org/0000-0002-1164-7614
Keler, Tibor
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02335918 at ClinicalTrials.govDocuments that mention this clinical trial
T lymphocyte-targeted immune checkpoint modulation in glioma
https://doi.org/10.1136/jitc-2019-000379
New emerging targets in cancer immunotherapy: CD27 (TNFRSF7)
https://doi.org/10.1136/esmoopen-2019-000629
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
https://doi.org/10.1136/jitc-2022-005147
-
Funding
Funding for this research was provided by:
NIH/NCI Cancer Center Support Grant (P30 CA008748)
Bristol Myers Squibb
Celldex Therapeutics, Inc.
- License Information
